Science Rabbit Newsletter

The loss of smell precedes severe cognitive issues by years in over 90% of patients with Alzheimer’s disease. Is a viral component of dementia quite literally right under our noses?

Before memory slips, the nose often signals trouble.

Loss of smell is one of the earliest flags in Alzheimer’s disease, and the wiring makes sense: odor signals travel from the nasal epithelium to the olfactory bulb and then to the entorhinal cortex and hippocampus—the memory hubs that fail first. Disruptions along this pathway can degrade the quality of input reaching those deep-brain circuits and, over time, promote neurodegeneration. That matters because the nose is a lifelong exposure zone and inflammatory hotspot, continually challenged by airborne microbes and reactivating neurotropic viruses. A growing body of epidemiologic and experimental work implicates infections as modifiable contributors to dementia risk. If repeated hits to these front-door circuits blunt the signals feeding the hippocampus, you don’t need an active hippocampal infection to start the slow burn. This piece examines the evidence—epidemiology, mechanisms, and open questions—behind a nose-centric view of Alzheimer’s disease.

What the Big Data Keeps Hinting At

Large, population-level studies have linked viral infections to higher rates of Alzheimer’s and related dementias.¹ The signal shows up with both “hit-and-run” infections (influenza, SARS-CoV-2) and lifelong herpesviruses that periodically reactivate, such as herpes simplex virus type 1 (HSV-1, the cold-sore virus) and varicella zoster virus (VZV, chickenpox/shingles).¹

Some consistent patterns:

• People with shingles on their face (herpes zoster ophthalmicus) show a markedly higher risk of a subsequent dementia diagnosis in the next few years.^2,3
• Antiviral treatment during shingles is associated with lower dementia risk compared with no treatment._⁴
• Vaccination matters: shingles vaccination and even annual flu shots correlate with reduced dementia diagnoses in multiple cohorts.^5-7
• Older adults with COVID-19 have shown elevated rates of post-infection cognitive diagnoses; whether vaccination blunts that long-term risk is still being clarified.⁸

These are associations, not proof of causation. But the direction of the arrows is hard to ignore: 

Infections up -> risk up 

Vaccines/Antivirals in -> risk down. 

Ongoing clinical studies are testing whether treating or preventing specific infections actually changes brain outcomes.

Related Article

The Link Between Shingles and Stroke Explained

The Awkward Gap: Where Are the Viruses in the Brain?

Here’s the problem. When scientists examine brains after death, they don’t consistently find these viruses in the regions most devastated by Alzheimer’s, like the hippocampus. That mismatch has spawned the “hit-and-run” idea: a virus visits, sparks a destructive cascade, and is cleared before anyone looks.

Skeptics push back: if stable DNA viruses such as HSV-1 or VZV were major drivers, shouldn’t we detect them more often in Alzheimer’s brains? And if there were ongoing viral encephalitis in memory centers, wouldn’t patients look more acutely ill? Those are fair questions—so the field has started looking just upstream.

The “Right Under Our Noses” Route: Olfaction

One of the shortest paths into the brain runs through the olfactory system. Odor signals travel from sensory neurons in the upper nasal cavity to the olfactory bulb (OB), then on to the entorhinal cortex and hippocampus—the very memory hubs that falter first in Alzheimer’s.

A few facts make this pathway compelling:

• Loss of smell commonly precedes measurable cognitive decline in Alzheimer’s.^9,10
• In animal models, blocking olfactory input can erode hippocampal structure and function—and even nudge amyloid pathology.¹¹
• The nose is a front-line battleground with the environment, facing a lifetime of microbes and immune skirmishes.
• Dormant herpesviruses, including VZV and HSV-1, reside in trigeminal ganglia with direct connections to olfactory circuits. During reactivation, they may bypass the nasal epithelium’s defenses and perturb the OB without marching into the hippocampus.¹²

In this framework, chronic or repeated inflammatory jolts in the olfactory bulb could degrade the quality of “smell-driven” input to the hippocampus. Think of it as sensory malnutrition: starve a circuit of healthy signals long enough, and it withers. You don’t need the virus to camp in the hippocampus to cause hippocampal trouble.

Local Infection, Distant Damage

Biology is full of examples where pathology in one region drives disease elsewhere. It’s plausible that episodic viral reactivation near olfactory circuits could tip downstream networks toward degeneration—especially in aging brains or in people with genetic risk. That would reconcile the epidemiology (infection risk up; antivirals/vaccines protective) with the spotty detection of virus in memory centers.

Where We Are Now

• The pattern is consistent: infections correlate with higher dementia risk, and prevention/treatment correlates with lower risk.
• The mechanism is evolving: a strict “virus in the hippocampus” model isn’t required; olfactory-bulb–centered inflammation and circuit disruption could fit the data.
• The verdict isn’t in: association is not causation. Ongoing clinical trials and mechanistic studies will decide how much of the Alzheimer’s burden is truly infection-linked—and who might benefit from antivirals or vaccines as brain-health tools.

If we’ve been laser-focused on the hippocampus because that’s where the damage is most obvious, we may have missed the earliest sparks. The viral piece of Alzheimer’s might not be deep in the brain at all—it might be, quite literally, right under our noses.